Evidence map›Paper›PMID 30008119›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2019

Is (S)-norketamine an alternative antidepressant for esketamine?

Kenji Hashimoto, Chun Yang

Abstract readLetter
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Ketamine in neuropsychiatric disorders: an update.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Esketamine: a glimmer of hope in treatment-resistant depression.European archives of psychiatry and clinical neuroscience · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kenji HashimotoDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan. hashimoto@faculty.chiba-u.jp.
Chun YangDepartment of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Funding

Japan Agency for Medical Research and Development JP18dm0107119National Natural Science Foundation of China 81703482
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntidepressive AgentsDepressionHumansKetamineAntidepressive AgentsEsketamineKetaminenorketamine

Identifiers

PMID30008119
PMCPMC6739277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.